Skip to main content
Top
Published in: Cardiovascular Diabetology 1/2024

Open Access 01-12-2024 | Gestational Diabetes | Research

Gestational diabetes mellitus and risk of long-term all-cause and cardiac mortality: a prospective cohort study

Authors: Qian Ying, Yao Xu, Ziyi Zhang, Luyi Cai, Yan Zhao, Liping Jin

Published in: Cardiovascular Diabetology | Issue 1/2024

Login to get access

Background

To investigate the association between gestational diabetes mellitus (GDM) without subsequent overt diabetes and long-term all-cause and cardiac mortality.

Methods

This prospective cohort study included 10,327 women (weighted population: 132,332,187) with a pregnancy history from the National Health and Nutrition Examination Survey (2007 to 2018). Participants were divided into three groups (GDM alone, overt diabetes, and no diabetes). Mortality data was linked from the National Death Index up to December 31, 2019. Multivariable Cox regression analysis was performed to examine the association between GDM alone and overt diabetes with all-cause mortality and cardiac mortality. Data analysis was performed from October 2022 to April 2023.

Results

Among the participants, 510 (weighted 5.3%) had GDM alone and 1862 (weighted 14.1%) had overt diabetes. Over a median follow-up period of 6.7 years (69,063 person-years), there were 758 deaths. The GDM group did not show an increased risk of all-cause mortality (hazard ratio [HR] 0.67; 95% CI, 0.25–1.84), while the overt diabetes group had a significantly higher risk (HR 1.95; 95% CI, 1.62–2.35). Similarly, the GDM group did not exhibit an elevated risk of cardiac mortality (HR 1.48; 95% CI, 0.50–4.39), whereas the overt diabetes group had a significantly higher risk (HR 2.37; 95% CI, 1.69–3.32). Furthermore, sensitivity analysis focusing on women aged 50 or above showed that the HR of GDM history for all-cause mortality was 1.14 (95% CI, 0.33–3.95) and the HR for cardiac mortality was 1.74 (95% CI, 0.49–6.20).

Conclusions

GDM alone was not associated with an increased risk of all-cause and cardiac mortality, while overt diabetes was significantly associated with both types of mortality.
Literature
1.
go back to reference Wang H, Li N, Chivese T, et al. IDF Diabetes Atlas: estimation of Global and Regional Gestational Diabetes Mellitus Prevalence for 2021 by International Association of Diabetes in Pregnancy Study Group’s Criteria. Diabetes Res Clin Pract. 2022;183:109050.CrossRefPubMed Wang H, Li N, Chivese T, et al. IDF Diabetes Atlas: estimation of Global and Regional Gestational Diabetes Mellitus Prevalence for 2021 by International Association of Diabetes in Pregnancy Study Group’s Criteria. Diabetes Res Clin Pract. 2022;183:109050.CrossRefPubMed
2.
go back to reference Shah NS, Wang MC, Freaney PM, et al. Trends in Gestational Diabetes at First Live Birth by Race and Ethnicity in the US, 2011–2019. JAMA. 2021;17(7):660.CrossRef Shah NS, Wang MC, Freaney PM, et al. Trends in Gestational Diabetes at First Live Birth by Race and Ethnicity in the US, 2011–2019. JAMA. 2021;17(7):660.CrossRef
3.
go back to reference O’Kelly AC, Michos ED, Shufelt CL, et al. Pregnancy and Reproductive Risk factors for Cardiovascular Disease in Women. Circ Res. 2022;18(4):652–72.CrossRef O’Kelly AC, Michos ED, Shufelt CL, et al. Pregnancy and Reproductive Risk factors for Cardiovascular Disease in Women. Circ Res. 2022;18(4):652–72.CrossRef
4.
go back to reference Parikh NI, Gonzalez JM, Anderson CAM et al. Adverse pregnancy outcomes and Cardiovascular Disease Risk: Unique Opportunities for Cardiovascular Disease Prevention in Women: A Scientific Statement from the American Heart Association. Circulation 2021;4;143(18). Parikh NI, Gonzalez JM, Anderson CAM et al. Adverse pregnancy outcomes and Cardiovascular Disease Risk: Unique Opportunities for Cardiovascular Disease Prevention in Women: A Scientific Statement from the American Heart Association. Circulation 2021;4;143(18).
5.
go back to reference Billionnet C, Mitanchez D, Weill A, et al. Gestational diabetes and adverse perinatal outcomes from 716,152 births in France in 2012. Diabetologia. 2017;60(4):636–44.CrossRefPubMedPubMedCentral Billionnet C, Mitanchez D, Weill A, et al. Gestational diabetes and adverse perinatal outcomes from 716,152 births in France in 2012. Diabetologia. 2017;60(4):636–44.CrossRefPubMedPubMedCentral
6.
go back to reference Vounzoulaki E, Khunti K, Abner SC et al. Progression to type 2 diabetes in women with a known history of gestational diabetes: systematic review and meta-analysis. BMJ 2020;13;m1361. Vounzoulaki E, Khunti K, Abner SC et al. Progression to type 2 diabetes in women with a known history of gestational diabetes: systematic review and meta-analysis. BMJ 2020;13;m1361.
7.
go back to reference Bragg F, Holmes MV, Iona A, et al. Association between Diabetes and cause-Specific Mortality in Rural and Urban areas of China. JAMA. 2017;17(3):280.CrossRef Bragg F, Holmes MV, Iona A, et al. Association between Diabetes and cause-Specific Mortality in Rural and Urban areas of China. JAMA. 2017;17(3):280.CrossRef
8.
go back to reference Rogot E, Feinleib M, Ockay KA, et al. On the feasibility of linking census samples to the National Death Index for epidemiologic studies: a progress report. Am J Public Health. 1983;73(11):1265–9.CrossRefPubMedPubMedCentral Rogot E, Feinleib M, Ockay KA, et al. On the feasibility of linking census samples to the National Death Index for epidemiologic studies: a progress report. Am J Public Health. 1983;73(11):1265–9.CrossRefPubMedPubMedCentral
9.
go back to reference WILLETT W C STAMPFERMJ, SPEIZER F E, et al. Test of the national death index. Am J Epidemiol. 1984;119(5):837–9.CrossRefPubMed WILLETT W C STAMPFERMJ, SPEIZER F E, et al. Test of the national death index. Am J Epidemiol. 1984;119(5):837–9.CrossRefPubMed
10.
go back to reference Cowper DC, Kubal JD, Maynard C, et al. A primer and comparative review of major US mortality databases. Ann Epidemiol. 2002;12(7):462–8.CrossRefPubMed Cowper DC, Kubal JD, Maynard C, et al. A primer and comparative review of major US mortality databases. Ann Epidemiol. 2002;12(7):462–8.CrossRefPubMed
12.
go back to reference Cao C, Friedenreich CM, Yang L. Association of Daily Sitting Time and leisure-time physical activity with Survival among US Cancer survivors. JAMA Oncol. 2022;1(3):395.CrossRef Cao C, Friedenreich CM, Yang L. Association of Daily Sitting Time and leisure-time physical activity with Survival among US Cancer survivors. JAMA Oncol. 2022;1(3):395.CrossRef
13.
go back to reference Frustaci A, Kajstura J, Chimenti C, et al. Myocardial cell death in human diabetes. Circ Res. 2000;87(12):1123–32.CrossRefPubMed Frustaci A, Kajstura J, Chimenti C, et al. Myocardial cell death in human diabetes. Circ Res. 2000;87(12):1123–32.CrossRefPubMed
14.
go back to reference McGavock JM, Lingvay I, Zib I, et al. Cardiac steatosis in diabetes mellitus: a 1H-magnetic resonance spectroscopy study. Circulation. 2007;116(10):1170–5.CrossRefPubMed McGavock JM, Lingvay I, Zib I, et al. Cardiac steatosis in diabetes mellitus: a 1H-magnetic resonance spectroscopy study. Circulation. 2007;116(10):1170–5.CrossRefPubMed
15.
go back to reference Kozakova M, Palombo C. Diabetes mellitus, arterial wall, and cardiovascular risk assessment. Int J Env Res Pub He. 2016;13(2):201.CrossRef Kozakova M, Palombo C. Diabetes mellitus, arterial wall, and cardiovascular risk assessment. Int J Env Res Pub He. 2016;13(2):201.CrossRef
16.
go back to reference Marwick TH, Ritchie R, Shaw JE, et al. Implications of underlying mechanisms for the recognition and management of diabetic cardiomyopathy. J Am Coll Cardiol. 2018;71(3):339–51.CrossRefPubMed Marwick TH, Ritchie R, Shaw JE, et al. Implications of underlying mechanisms for the recognition and management of diabetic cardiomyopathy. J Am Coll Cardiol. 2018;71(3):339–51.CrossRefPubMed
17.
go back to reference Bhatti JS, Sehrawat A, Mishra J, et al. Oxidative stress in the pathophysiology of type 2 diabetes and related complications: current therapeutics strategies and future perspectives. Free Radical Bio Med. 2022;184:114–34.CrossRef Bhatti JS, Sehrawat A, Mishra J, et al. Oxidative stress in the pathophysiology of type 2 diabetes and related complications: current therapeutics strategies and future perspectives. Free Radical Bio Med. 2022;184:114–34.CrossRef
18.
go back to reference Sweeting A, Wong J, Murphy HR, et al. A clinical update on gestational diabetes Mellitus. Endocr Rev. 2022;26(5):763–93.CrossRef Sweeting A, Wong J, Murphy HR, et al. A clinical update on gestational diabetes Mellitus. Endocr Rev. 2022;26(5):763–93.CrossRef
20.
go back to reference Catalano PM, McIntyre HD, Cruickshank JK, et al. The hyperglycemia and adverse pregnancy outcome study: associations of GDM and obesity with pregnancy outcomes. Diabetes Care. 2012;35(4):780–6.CrossRefPubMedPubMedCentral Catalano PM, McIntyre HD, Cruickshank JK, et al. The hyperglycemia and adverse pregnancy outcome study: associations of GDM and obesity with pregnancy outcomes. Diabetes Care. 2012;35(4):780–6.CrossRefPubMedPubMedCentral
21.
go back to reference Farrar D, Fairley L, Santorelli G, et al. Association between hyperglycaemia and adverse perinatal outcomes in south Asian and white British women: analysis of data from the born in Bradford cohort. Lancet Diabetes Endocrinol. 2015;3(10):795–804.CrossRefPubMedPubMedCentral Farrar D, Fairley L, Santorelli G, et al. Association between hyperglycaemia and adverse perinatal outcomes in south Asian and white British women: analysis of data from the born in Bradford cohort. Lancet Diabetes Endocrinol. 2015;3(10):795–804.CrossRefPubMedPubMedCentral
22.
go back to reference Venkatesh KK, Lynch CD, Powe CE, et al. Risk of adverse pregnancy outcomes among pregnant individuals with gestational diabetes by race and ethnicity in the United States, 2014–2020. JAMA. 2022;327(14):1356–67.CrossRefPubMedPubMedCentral Venkatesh KK, Lynch CD, Powe CE, et al. Risk of adverse pregnancy outcomes among pregnant individuals with gestational diabetes by race and ethnicity in the United States, 2014–2020. JAMA. 2022;327(14):1356–67.CrossRefPubMedPubMedCentral
23.
go back to reference Ye W, Luo C, Huang J et al. Gestational diabetes mellitus and adverse pregnancy outcomes: systematic review and meta-analysis. BMJ 2022;377. Ye W, Luo C, Huang J et al. Gestational diabetes mellitus and adverse pregnancy outcomes: systematic review and meta-analysis. BMJ 2022;377.
24.
go back to reference Fadl H, Magnuson A, Östlund I, et al. Gestational diabetes mellitus and later cardiovascular disease: a Swedish population based case–control study. BJOG. 2014;121(12):1530–6.CrossRefPubMedPubMedCentral Fadl H, Magnuson A, Östlund I, et al. Gestational diabetes mellitus and later cardiovascular disease: a Swedish population based case–control study. BJOG. 2014;121(12):1530–6.CrossRefPubMedPubMedCentral
25.
go back to reference Christensen MH, Rubin KH, Petersen TG, et al. Cardiovascular and metabolic morbidity in women with previous gestational diabetes mellitus: a nationwide register-based cohort study. Cardiovasc Diabetol. 2022;9(1):179.CrossRef Christensen MH, Rubin KH, Petersen TG, et al. Cardiovascular and metabolic morbidity in women with previous gestational diabetes mellitus: a nationwide register-based cohort study. Cardiovasc Diabetol. 2022;9(1):179.CrossRef
26.
go back to reference Lee SM, Shivakumar M, Park JW, et al. Long-term cardiovascular outcomes of gestational diabetes mellitus: a prospective UK Biobank study. Cardiovasc Diabetol. 2022;29(1):221.CrossRef Lee SM, Shivakumar M, Park JW, et al. Long-term cardiovascular outcomes of gestational diabetes mellitus: a prospective UK Biobank study. Cardiovasc Diabetol. 2022;29(1):221.CrossRef
27.
go back to reference Echouffo-Tcheugui JB, Guan J, Retnakaran R, et al. Gestational diabetes and Incident Heart failure: a Cohort Study. Diabetes Care. 2021;1(10):2346–52.CrossRef Echouffo-Tcheugui JB, Guan J, Retnakaran R, et al. Gestational diabetes and Incident Heart failure: a Cohort Study. Diabetes Care. 2021;1(10):2346–52.CrossRef
28.
go back to reference Yu Y, Soohoo M, Sørensen HT, et al. Gestational diabetes Mellitus and the risks of overall and type-specific Cardiovascular diseases: a Population- and sibling-matched cohort study. Diabetes Care. 2022;1(1):151–9.CrossRef Yu Y, Soohoo M, Sørensen HT, et al. Gestational diabetes Mellitus and the risks of overall and type-specific Cardiovascular diseases: a Population- and sibling-matched cohort study. Diabetes Care. 2022;1(1):151–9.CrossRef
29.
go back to reference Kramer CK, Campbell S, Retnakaran R. Gestational diabetes and the risk of cardiovascular disease in women: a systematic review and meta-analysis. Diabetologia. 2019;62(6):905–14.CrossRefPubMed Kramer CK, Campbell S, Retnakaran R. Gestational diabetes and the risk of cardiovascular disease in women: a systematic review and meta-analysis. Diabetologia. 2019;62(6):905–14.CrossRefPubMed
30.
go back to reference Retnakaran R. Hyperglycemia in pregnancy and its implications for a woman’s future risk of cardiovascular disease. Diabetes Res Clin Pr. 2018;145:193–9.CrossRef Retnakaran R. Hyperglycemia in pregnancy and its implications for a woman’s future risk of cardiovascular disease. Diabetes Res Clin Pr. 2018;145:193–9.CrossRef
32.
go back to reference Retnakaran R, Luo J, Shah BR. Gestational diabetes in young women predicts future risk of serious liver disease. Diabetologia. 2019;62(2):306–10.CrossRefPubMed Retnakaran R, Luo J, Shah BR. Gestational diabetes in young women predicts future risk of serious liver disease. Diabetologia. 2019;62(2):306–10.CrossRefPubMed
33.
go back to reference Ajmera VH, Gunderson EP, VanWagner LB, et al. Gestational diabetes Mellitus is strongly Associated with non-alcoholic fatty liver disease. Am J Gastroenterol. 2016;111(5):658–64.CrossRefPubMedPubMedCentral Ajmera VH, Gunderson EP, VanWagner LB, et al. Gestational diabetes Mellitus is strongly Associated with non-alcoholic fatty liver disease. Am J Gastroenterol. 2016;111(5):658–64.CrossRefPubMedPubMedCentral
34.
go back to reference Rawal S, Olsen SF, Grunnet LG, et al. Gestational diabetes Mellitus and renal function: a prospective study with 9- to 16-Year follow-up after pregnancy. Diabetes Care. 2018;1(7):1378–84.CrossRef Rawal S, Olsen SF, Grunnet LG, et al. Gestational diabetes Mellitus and renal function: a prospective study with 9- to 16-Year follow-up after pregnancy. Diabetes Care. 2018;1(7):1378–84.CrossRef
35.
go back to reference Christensen MH, Andersen MS, Rubin KH, et al. Psychiatric Morbidity in Women with previous gestational diabetes Mellitus: a Nationwide Register-based Cohort Study. Diabetes Care. 2023;1(5):1076–84.CrossRef Christensen MH, Andersen MS, Rubin KH, et al. Psychiatric Morbidity in Women with previous gestational diabetes Mellitus: a Nationwide Register-based Cohort Study. Diabetes Care. 2023;1(5):1076–84.CrossRef
36.
go back to reference Powe CE, Tobias DK, Michels KB, et al. History of gestational diabetes Mellitus and risk of incident invasive breast Cancer among Parous women in the nurses’ Health Study II prospective cohort. Cancer Epidem Biomar. 2017;1(3):321–7.CrossRef Powe CE, Tobias DK, Michels KB, et al. History of gestational diabetes Mellitus and risk of incident invasive breast Cancer among Parous women in the nurses’ Health Study II prospective cohort. Cancer Epidem Biomar. 2017;1(3):321–7.CrossRef
Metadata
Title
Gestational diabetes mellitus and risk of long-term all-cause and cardiac mortality: a prospective cohort study
Authors
Qian Ying
Yao Xu
Ziyi Zhang
Luyi Cai
Yan Zhao
Liping Jin
Publication date
01-12-2024
Publisher
BioMed Central
Published in
Cardiovascular Diabetology / Issue 1/2024
Electronic ISSN: 1475-2840
DOI
https://doi.org/10.1186/s12933-024-02131-3

Other articles of this Issue 1/2024

Cardiovascular Diabetology 1/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine